R&D News | pharmaphorum

News

Boehringer moves obesity therapy into phase 3

Boehringer Ingelheim and Zealand Pharma have kicked off three phase 3 trials of obesity drug candidate survodutide, in patients with and without diabetes, in the hope of b

News

uniQure sheds a fifth of its staff and half its R&D

Netherlands gene therapy company uniQure has said it will shed 20% of its workforce, around 114 jobs, and slash its R&D projects in an effort to extend its cash reserv

News

Sanofi buys into Teva’s anti-TL1A therapy for IBD

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva

News

UK Biobank study “will shape drug discovery”

A landmark study drawing on data from UK Biobank has generated a first-of-its-kind dataset of the interactions between genes and proteins that could unlock myriad avenues for research

News

Moderna eyes 2025 approval for COVID, flu combination jab

Moderna’s combined mRNA-based vaccine for COVID-19 and seasonal influenza has been shown to be at least as effective as jabs given separately in a phase 1/2 trial, setting

News

Roche app relieves diabetes distress in clinical trial

A digital health application (DiGA) has been shown to relieve the distress that patients can experience when managing diabetes, which can compromise their care, in a rando

Boehringer moves obesity therapy into phase 3

uniQure sheds a fifth of its staff and half its R&D

Sanofi buys into Teva’s anti-TL1A therapy for IBD

UK Biobank study “will shape drug discovery”

Moderna eyes 2025 approval for COVID, flu combination jab

Roche app relieves diabetes distress in clinical trial

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks